相关实验视频

Updated: Jul 1, 2025

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

预测的效果度的remimazolam用于i-gel插入:一个前性随机对照研究

Hisako Nishimoto¹, Tadayoshi Kurita², Mikihiro Shimizu³

¹Department of Anesthesiology and Intensive Care, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, 431-3192, Japan. 41237099@hama-med.ac.jp.

Journal of clinical monitoring and computing

|March 4, 2024

概括

这项研究确定了用于i-gel插入的雷米马佐拉姆有效剂量. 至少1.57微克/毫升的效果部位度是成功放置i-gel与雷米马佐拉姆麻醉时所需的.

科学领域:

麻醉学麻醉学
药理学药理学是指药理学的学科.

背景情况:

雷米马佐拉姆是一种新型的短效二胺.
成功插入I-gel需要适当的镇静和麻醉.

研究的目的:

确定用于i-gel插入的雷米马佐拉姆的50%和95%效果部位度 (EC50和EC95).
评价雷米马佐拉姆在与芬太尼同时使用时促进i-gel安置的疗效.

主要方法:

30名患者被随机分配到五组,接受不同剂量的雷米马佐拉姆.
效果部位度保持不变,并且芬太尼尔被同时使用.
使用试管体分析计算EC50和EC95值.

主要成果:

在i-gel插入时,雷米马佐拉姆的EC50为0.88μg/ml (95% CI,0.65-1.11).
雷米马佐拉姆的EC95值为1.57μg/ml (95% CI,1.09-2.05). 在此期间,该药物使用了
为了成功插入i-gel,即使使用芬太尼,效果部位度≥1.57μg/ml也是必要的.

结论:

雷米马佐拉姆有效地促进了i-gel的插入.
建议在效果部位度为1.57μg/ml的雷米马佐拉姆,以确保成功安装i-gel.
这项研究为雷米马佐拉姆的使用提供了关键的药理动力学和药理动力学数据.

关键词:

剂量-反应关系剂量-反应效果场所的度效果场所的度雷米马佐拉姆 (Remimazolam) 是一种药物.我-凝是一种.

更多相关视频

Assessing Changes in Volatile General Anesthetic Sensitivity of Mice after Local or Systemic Pharmacological Intervention

Assessing Changes in Volatile General Anesthetic Sensitivity of Mice after Local or Systemic Pharmacological Intervention

Published on: October 16, 2013

Intraoperative Visualization of Subretinal Injection and Retinal Detachment in Rats

Intraoperative Visualization of Subretinal Injection and Retinal Detachment in Rats

Published on: March 7, 2025

相关概念视频

Sedatives and Hypnotics Drugs: Miscellaneous Agents

Sedatives and Hypnotics Drugs: Miscellaneous Agents

Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...